Toxicity of doxorubicin entrapped within long-circulating liposomes

Journal of Controlled Release

Volumn 44, Issue 1, 1997, Pages 1-9

  Daemen, Toos ^a   Regts, Joke ^a   Meesters, Maarten ^a   Ten Kate, Marian T ^b   Bakker Woudenberg, Irma A J M ^b   Scherphof, Gerrit L ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Bacterial blood clearance capacity; Doxorubicin; Long circulating liposomes; Phagocytic capacity; Rat liver macrophages

Indexed keywords

CHOLESTEROL; DOXORUBICIN; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MACROPHAGE; MALE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT;

EID: 0031015561     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01501-5     Document Type: Article

References (22)

1. A.H. Herman, A. Rahman, V.J. Ferrans, J.A. Vick and P.S. Schein, Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation, Cancer Res. 43 (1983) 5427-5432.
2. A. Rahman, A. Joher and J.R. Neefe, Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Br. J. Cancer 54 (1986) 401-408.
3. T. Daemen, T. Hofstede, M.T. Ten Kate, I.A.J.M. Bakker-Woudenberg and G.L. Scherphof, Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages, Int. J. Cancer 61 (1995) 716-721.
4. E.G. Mayhew, M.H. Goldrosen, J. Vaage and Y.M. Rustum, Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38, J. Natl. Cancer Inst. 78 (1987) 707-713.
5. L.D. Mayer, M.B. Bally, P.R. Cullis, S.L. Wilson and J.T. Emerman, Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor, Cancer Lett. 53 (1990) 183-190.
6. G. Storm, F.H. Roerdink, P.A. Steerenberg, W.H. De Jong and D.J.A. Crommelin, Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model, Cancer Res. 47 (1987) 3366-3372.
7. Q. Qian, M.A. Jutila, N. Van Rooijen and J.E. Cutler, Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis, J. Immunol. 152 (1994) 5000-5008.
8. M.S. Roh, M.P. Kahky, C. Oyedeji, J. Klostergaard, L. Wang, S.A. Curley and E. Lotzova, Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases, Clin. Exp. Metastasis 10 (1992) 317-327.
9. G. Heuff, H.S.A. Oldenburg, H. Boutkan, J.J. Visser, R.H.J. Beelen, N. Van Rooijen, C.D. Dijkstra and S. Meyer, Enhanced tumor growth in the rat liver after selective elimination of Kupffer cells, Cancer Immunol. Immunother. 37 (1993) 125-130.
10. M. Harrison, D. Tomlinson and S. Stewart, Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma, J. Clin. Oncol. 13 (1995) 914-920.
11. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang and Y. Barenholz, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54 (1994) 8987-8992.
12. M.C. Woodle and D.D. Lasic, Sterically stabilized liposomes, Biochim. Biophys. Acta, 1113 (1992) 171-199.
13. L.D. Mayer, L.C.L. Tai, M.B. Bally, G.N. Mitilenes, R.S. Ginsberg and P.R. Cullis, Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients, Biochim. Biophys. Acta 1025 (1990) 143-151.
14. T. Daemen, A. Veninga, F.H. Roerdink and G.L. Scherphof, In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide, Cancer Res. 46 (1986) 4330-4335.
15. Y. Stein, Y. Kleinman, G. Halperin and O. Stein, Hepatic retention and elimination of cholesteryl linoleylether after injection of labeled acetylated LDL or chylomicrons, Biochim. Biophys. Acta 750 (1983) 300-305.
16. I.A.J.M. Bakker-Woudenberg, M.T. Ten Kate, L.E.T. Stearne-Cullen and M.C. Woodle, Efficacy of gentamicin or ceftazidine entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae infected lung tissue, J. Infect. Dis. 171 (1995) 938-947.
17. S.K. Huang, E. Mayhew, S. Gilani, D.D. Lasic, F.J. Martin and D. Papahadjopoulos, Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma, Cancer Res. 52 (1992) 6774-6781.
18. T. Daemen, J. Koudstaal, G.L. Scherphof and M.J. Hardonk, Population kinetics of rat liver macrophages after intravenous administration of liposome-encapsulated MDP. In: E. Wisse, D.L. Knook and K. Decker (Eds.), Cells of the Hepatic Sinusoid, Vol. 2, The Kupffer Cell Foundation, Rijswijk, The Netherlands, 1989, pp. 400-405.
19. M.J. Parr, M.B. Bally and P.R. Cullis, The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade, Biochim. Biophys. Acta, 1168 (1993) 249-252.
20. J.R. Bogner, U. Kronawitter, B. Rolinski, K. Truebenbach and F.-D. Goebel, Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma, J. Acquir. Immune. Defic. Syndr. 7 (1994) 463-468.
21. U.R. Hengge, N.H. Brockmeyer, R. Raßhofer and M. Goos, Fatal hepatic failure with liposomal doxorubicin, Lancet 341 (1993) 383-384.
22. J. Hosoda, S. Unezaki, K. Maruyama, S. Tsuchiya and M. Iwatsuru, Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes, Biol. Pharm. Bull. 18 (1995) 1234-1237.